Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype

Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find MYC-associated epigenetic depende...

Descripción completa

Detalles Bibliográficos
Autores principales: Orben, Felix, Lankes, Katharina, Schneeweis, Christian, Hassan, Zonera, Jakubowsky, Hannah, Krauß, Lukas, Boniolo, Fabio, Schneider, Carolin, Schäfer, Arlett, Murr, Janine, Schlag, Christoph, Kong, Bo, Öllinger, Rupert, Wang, Chengdong, Beyer, Georg, Mahajan, Ujjwal M., Xue, Yonggan, Mayerle, Julia, Schmid, Roland M., Kuster, Bernhard, Rad, Roland, Braun, Christian J., Wirth, Matthias, Reichert, Maximilian, Saur, Dieter, Schneider, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220834/
https://www.ncbi.nlm.nih.gov/pubmed/35439169
http://dx.doi.org/10.1172/jci.insight.151353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220834/
https://www.ncbi.nlm.nih.gov/pubmed/35439169
http://dx.doi.org/10.1172/jci.insight.151353

Ejemplares similares